

ONCOLOGY III PANEL

EDITORIAL BOARD LIAISON

Emilie L. Karpiuk, Pharm.D., BCPS, BCOP
Oncology Pharmacist
Department of Pharmacy
Froedtert Hospital
Milwaukee, Wisconsin

GYNECOLOGIC CANCERS

Author

Judith A. Smith, Pharm.D., FCCP, BCOP, FISOPP
Associate Professor
Department of Gynecologic Oncology and
Reproductive Medicine
The University of Texas M.D. Anderson Cancer
Center
Assistant Professor
Department of Obstetrics, Gynecology and
Reproductive Sciences
The University of Texas Health Sciences Center at
Houston Medical School
Houston, Texas

Reviewers

Anne L. Hume, Pharm.D., FCCP, BCPS
Professor of Pharmacy
Department of Pharmacy Practice
University of Rhode Island
Kingston, Rhode Island
Adjunct Professor of Family Medicine
Alpert School of Medicine at Brown University
Providence, Rhode Island

Helen M. LoSasso, Pharm.D., BCPS
Clinical Manager of Pharmacy Services
Pharmacy Department
Kennedy University Hospital
Stratford, New Jersey

Dayna L. McCauley, Pharm.D., BCOP
Oncology Pharmacist, Gynecologic Oncology
Department of Pharmacy
State University of New York at Stony Brook
Stony Brook, New York

NON-HODGKIN LYMPHOMA

Author

Viet Q. Ho, Pharm.D., BCOP
Clinical Coordinator – Malignant Hematology
Department of Pharmacy
Moffitt Cancer Center
Tampa, Florida

Reviewers

Ola A. Adejuwon, Pharm.D., BCPS
Clinical Pharmacy Specialist
Department of Pharmacy
North Cypress Medical Center
Cypress, Texas

Shannon W. Finks, Pharm.D., BCPS (AQ Cardiology)
Associate Professor
Department of Clinical Pharmacy
University of Tennessee College of Pharmacy
Clinical Pharmacy Specialist, Cardiology
Department of Pharmacy
VA Medical Center
Memphis, Tennessee

Jamie Shapiro, Pharm.D., BCOP
*Clinical Coordinator – Blood and Stem Cell
Transplantation*
Department of Pharmacy
Moffitt Cancer Center
Tampa, Florida

UPDATES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

Authors

Patrick J. Kiel, Pharm.D., BCPS, BCOP
*Clinical Pharmacy Specialist, Hematology/Stem Cell
Transplant*
Department of Pharmacy
Indiana University Simon Cancer Center
Indianapolis, Indiana

Christopher A. Fausel, Pharm.D., BCPS, BCOP
Clinical Manager, Oncology Pharmacy
Department of Pharmacy
Indiana University Health
Indianapolis, Indiana

Reviewers

Clarence Chant, Pharm.D., FCCP, FCSHP, BCPS
Clinical Pharmacy Specialist
Critical Care/Research, Pharmacy Department
St. Michael's Hospital
Toronto, Ontario, Canada

Helen L. Leather, BSP Pharm
Scientific Director
Nucleus Holdings
New York, New York
Clinical Pharmacist Consultant
Department of Pharmacy
Shands at the University of Florida
Gainesville, Florida

April D. Miller, Pharm.D., BCPS
Assistant Professor
Department of Clinical Pharmacy and Outcomes
Sciences
South Carolina College of Pharmacy
University of South Carolina
Columbia, South Carolina

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 6, Oncology III chapters:

Julia Elenbaas, Pharm.D.
Belton, Missouri

Mary Lee, Pharm.D., FCCP, BCPS
Vice President and Chief Academic Officer
Pharmacy and Health Sciences Education
Midwestern University
Professor of Pharmacy Practice
Midwestern University
Chicago College of Pharmacy
Downers Grove, Illinois

Dale Whitby, Pharm.D., BCPS
Managing Editor, Clinical Content
Elsevier/Gold Standard
Midlothian, Virginia

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: David Baribeault (Amgen, Watson, Eisai); Shannon W. Finks (Novartis Pharmaceuticals); Myke Green (Merck, Sanofi-Aventis); Brian A. Hemstreet (Conexus Health); Viet Ho (Cephalon Oncology); Lisa C. Hutchison (Arkansas Medicaid, Arkansas Foundation for Medical Care); Paul Hutson (Projections Research, Inc., Mithridion); Patrick Kiel (Genzyme, Sanofi-Aventis); Michelle Richardson (Amgen, QualityMetric); Sarah Scarpace (Pfizer, TopoTarget, Millennium Pharmaceuticals, Merck); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, Annals of Pharmacotherapy); Jamie Shapiro (Genzyme); Jeffrey T. Sherer (Sturges-Weber Foundation); Judith Smith (AdvoCare);

Stock Ownership: Katherine H. Chessman (Procter & Gamble [spouse or significant other]); Lisa C. Hutchison (Cardinal Health); Emilie Karpiuk (Cardinal Health);

Royalties: William Figg (Kaplan, Springer); Lisa C. Hutchison (ASHP); Helen Leather (Genzyme, Novartis, Bayer, Amgen, Pfizer)

Grants: William Figg (NIH, Tracon); Brian A. Hemstreet (AstraZeneca); Anne L. Hume (AHRQ [two grants],

HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Michelle Richardson (NIH NIDDK [two grants]); Judith Smith (Merck, SignPath Pharma, Amino UP Chemical)

Honoraria: David Baribeault (Amgen, Eisai, Roche); Christopher Fausel (Amgen, Millennium Pharmaceuticals); Lisa C. Hutchison (ACCP, ASHP); Patrick Kiel (Genzyme); Helen LoSasso (New Jersey Society of Health-System Pharmacists, New Jersey Pharmacists Association); April Miller (Boehringer-Ingelheim, ZymoGenetics); Michelle Richardson (Amgen); Jamie Shapiro (Genzyme)

Other:

Nothing to Disclose: Ola Adejuwon, Laura Bobolts, Janet Bramell, Julianna Merten, Clarence Chant, Margaret Charpentier, Michelle Ganoff, Christy Harris, Kellie Jones, Shaun Keegan, Bernard Lee, Dayna McCauley, Marianne McCollum, April Miller, Jolynn Sessions, Sachin Shah, Audrea Szabatura, Sarah Ussery

ROLE OF ACCP: ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmacy Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at www.bpsweb.org/recertification/general.cfm.

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties
2215 Constitution Avenue NW
Washington, DC 20037
(202) 429-7591
www.bpsweb.org